Picture of Camurus AB logo

CAMX Camurus AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+1.99%
3m+34.49%
6m+86.04%
1yr+34.98%
Volume Change (%)
10d/3m-7.39%
Price vs... (%)
52w High-7.46%
50d MA+10.3%
200d MA+36.78%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)42.81
PEG Ratio (f)0.43
EPS Growth (f)7,804.76%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value14.3
Price to Tang. Book14.7
Price to Free Cashflown/a
Price to Sales16.18
EV to EBITDA74,416.78

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1.41%
Return on Equity-1.49%
Operating Margin-1.63%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Camurus AB EPS forecast chart

Profile Summary

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
October 8th, 2004
Public Since
December 3rd, 2015
No. of Employees
157
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
55,006,943

CAMX Share Price Performance

Upcoming Events for CAMX

Q3 2022 Camurus AB Earnings Release

Similar to CAMX

Picture of Biogaia AB logo

Biogaia AB

se flag iconOMX Nordic Exchange Stockholm

Picture of BoneSupport Holding AB logo

BoneSupport Holding AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Calliditas Therapeutics AB logo

Calliditas Therapeutics AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Cline Scientific AB logo

Cline Scientific AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Corline Biomedical AB logo

Corline Biomedical AB

se flag iconOMX Nordic Exchange Stockholm

FAQ

Or unlock with your email

Or unlock with your email